|Bid||18.53 x 1800|
|Ask||19.00 x 1000|
|Day's Range||19.08 - 19.39|
|52 Week Range||0.77 - 20.48|
|Beta (3Y Monthly)||2.03|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.00|
Nes-Ziona, Israel, June 18, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Australian Patent Office (IP Australia) granted a new patent (#2013353573) covering ALLOCETRATM, the company’s immunotherapy product. This new patent adds intellectual property protection, including methods, uses and pharmaceutical compositions in Australia. Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing.
Nes Ziona, Israel, June 06, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (ENLV), a clinical-stage immunotherapy company, today provided a clinical update on the positive safety profile of its off-the-shelf cell therapy, AllocetraTM, in the first three severe sepsis patients, as part of its ongoing Phase Ib clinical trial. This is the first infusion of off-the-shelf AllocetraTM (“OTS Allocetra”) in human subjects. Enlivex has developed OTS Allocetra as a second-generation cell therapy to the matched-donor Allocetra product, which has demonstrated a robust safety and clinical efficacy profile in a Phase IIa clinical trial for the prevention of GvHD in patients following bone-marrow transplantation.
Nes-Ziona, Israel, May 30, 2019 -- Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced that company management will make a.
Enlivex is eligible to receive additional grants from the IIA for this clinical program in 2020 and 2021, subject to certain terms and conditions. To date, Enlivex has received a total of approximately $4.2 million of grants from the IIA. The IIA is an independent, publicly funded agency charged with fostering the development of industrial R&D within the State of Israel.
Enlivex Therapeutics Ltd. (ENLV), a clinical-stage immunotherapy company, today announced the final closing of a private placement financing of ordinary shares priced at $12.25 per share, raising a total of approximately $8.4 million. The final closing of $3.0 million on April 4, 2019 follows the initial closing of approximately $5.4 million previously announced by Enlivex on March 26, 2019. Enlivex is developing a novel immunotherapy candidate with a unique mode of action that targets clinical indications defined as “life-threatening, unmet medical need,” such as preventing or treating complications associated with bone-marrow transplantations, sepsis – which is the third-leading cause of mortality in the United States after cardiovascular and cancer diseases, as well as treatment of solid tumors via immune checkpoint reprogramming, potentially increasing the efficacy of CAR-T, TCR and other anti-cancer therapies.
Nes-Ziona, Israel, April 04, 2019 -- Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced that company management will make a.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced its Nasdaq listing under the symbol “ENLV” and the concurrent closing of a private placement of ordinary shares priced at $12.25 per share.